Skip Navigation


NDT Advance Access originally published online on April 19, 2005
Nephrology Dialysis Transplantation 2005 20(6):1232-1237; doi:10.1093/ndt/gfh829
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/6/1232    most recent
gfh829v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lien, Y.-H. H.
Right arrow Articles by Whittman, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lien, Y.-H. H.
Right arrow Articles by Whittman, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Preliminary Communication

Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

Yeong-Hau H. Lien, Arnold L. Silva and David Whittman

Department of Medicine, University of Arizona, Tucson, AZ 85724, USA

Correspondence and offprint requests to: Yeong-Hau H. Lien, MD, PhD, Nephrology Section, Department of Medicine, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA. Email: lien{at}email.arizona.edu

Background. Cinacalcet, a calcimimetic agent, is effective in treating both primary and secondary hyperparathyroidism. Because hyperparathyroidism induces mineralized bone loss, we investigated the effects of cinacalcet treatment on bone mineral density (BMD) in patients with secondary hyperparathyroidism due to chronic kidney disease.

Methods. Ten patients who were receiving haemodialysis and four patients, who had stage 4 chronic kidney disease participated and completed the multicentre, randomized, double-blind, placebo-controlled trials evaluating the safety and efficacy of cinacalcet for treating secondary hyperparathyroidism. The efficacy of cinacalcet was assessed by plasma intact parathyroid hormone (iPTH) levels. A dual energy X-ray absorptiometry was performed to measure the BMD of total proximal femurs and lumbar spine (L2–L4) before and after 26 weeks of treatment.

Results. Cinacalcet reduced iPTH from 912±296 to 515±359 pg/ml in haemodialysis patients and from 210±46 to 56±51 pg/ml in pre-dialysis patients (means±SD; both P<0.05). When data from haemodialysis and pre-dialysis patients were pooled for analysis, cinacalcet treatment increased proximal femur BMD from 0.945±0.169 to 0.961±0.174 g/cm2 (P<0.05), but did not affect lumbar spine BMD. There was a correlation between the change in femur BMD and the change in iPTH during the study period (R2 = 0.39, P<0.05).

Conclusions. Secondary hyperparathyroidism is associated with progressive bone loss. Suppression of plasma iPTH with cinacalcet appears to reverse bone loss in the proximal femur, but does not affect BMD of the lumbar spine. A larger study is warranted to confirm that cinacalcet has a beneficial effect on the skeletal system in patients with secondary hyperparathyroidism.

Keywords: bone mineral density; calcium-sensing receptor; cinacalcet; cortical bone; secondary hyperparathyroidism; trabecular bone


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. Kamar, I. Gennero, L. Spataru, L. Esposito, J. Guitard, L. Lavayssiere, O. Cointault, P. Gandia, D. Durand, and L. Rostaing
Pharmacodynamic effects of cinacalcet after kidney transplantation: once- versus twice-daily dose
Nephrol. Dial. Transplant., June 16, 2008; (2008) gfn345v1.
[Abstract] [Full Text] [PDF]

Home page
 NDT PlusHome page
R. Eriguchi, J. Umakoshi, Y. Tominaga, and Y. Sato
Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
NDT Plus, May 25, 2008; (2008) sfn058v1.
[Full Text] [PDF]

Home page
 NDT PlusHome page
J. Cunningham, J. Floege, G. London, M. Rodriguez, and C. M. Shanahan
Clinical Outcomes in Secondary Hyperparathyroidism and the Potential Role of Calcimimetics
NDT Plus, January 1, 2008; 1(suppl_1): i29 - i35.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
M. Buemi, G. Coppolino, A. Sturiale, I. Villari, E. Crasci, S. Campo, L. Nostro, C. Aloisi, and A. Villari
Cinacalcet modifies the pH of solutions in vitro: possible implications for gastro-intestinal side effects in vivo
Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2409 - 2411.
[Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
A. L. Serra, R. Savoca, A. R. Huber, U. Hepp, A. Delsignore, M. Hersberger, and R. P. Wuthrich
Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients
Nephrol. Dial. Transplant., February 1, 2007; 22(2): 577 - 583.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
N. Velasco, M. S. MacGregor, A. Innes, and I. G. MacKay
Successful treatment of calciphylaxis with cinacalcet--an alternative to parathyroidectomy?
Nephrol. Dial. Transplant., July 1, 2006; 21(7): 1999 - 2004.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.